FDA Approved! Abbott FreeStyle Libre® 3 Continuous Glucose Monitor, Ages 4+
The FDA cleared the FreeStyle Libre 3 continuous glucose monitor (CGM) for children and adults ages 4 and up with diabetes
More CGMs Now Covered by Medicare
In March 2022, Medicare beneficiaries became eligible for coverage for a greater number of CGMs than ever before. Due to a final rule issued on December 21, 2021 by the Centers for Medicare and Medicaid Services (CMS), any CGM that connects with an insulin pump or a standalone receiver will be covered by Medicare for […]
Insulin Affordability? Yes, Please: Breakthrough T1D Joins Civica to Make Low-Cost Insulin Available to All Americans
In conjunction with leading partners, Breakthrough T1D lends its support to Civica, to help combat a nationwide insulin affordability crisis.
Breakthrough T1D Statement: President’s Comments about Insulin Affordability During State of the Union
Breakthrough T1D is glad President Biden used the State of the Union to address the insulin affordability crisis, which has had devastating consequences in the diabetes community for far too long. Joshua Davis, the young man with type 1 diabetes who joined the First Lady in the gallery, was one of the Breakthrough T1D Children’s […]
Helping the Diabetes Community in Ukraine – 6/1 Update
Guide on how to support the diabetes community in Ukraine.
Celebrating the Best of 2021
In 2021, Breakthrough T1D has seen tremendous progress in accelerating cures, improving lives, and advocating for people with type 1 diabetes and their loved ones.
Find Your Something
A resident physician and T1D dad—who also lives with an autoimmune disease—shares his call to action to support Breakthrough T1D and research to cure T1D and improve lives.
On Medicare? Accessing CGMs Just Got Easier
A recent update to continuous glucose monitor (CGM) coverage requirements will make it easier for people covered by Medicare to access CGM technology.
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for at-risk individuals.
Breakthrough T1D Advocates Have Been Hard at Work
Through these meetings, advocates give a voice to those impacted by T1D.
